Sufferers had a decreased threat of growing lengthy COVID after taking Paxlovid, and the advantages had been seen amongst those that had been vaccinated and unvaccinated.
Stephanie Nano/AP
conceal caption
toggle caption
Stephanie Nano/AP
Sufferers had a decreased threat of growing lengthy COVID after taking Paxlovid, and the advantages had been seen amongst those that had been vaccinated and unvaccinated.
Stephanie Nano/AP
It is well-documented that Paxlovid — a 5-day course of antiviral drugs from Pfizer — can scale back the chance of hospitalization in COVID-19 sufferers who usually tend to develop extreme sickness.
Now, researchers from the Veterans Well being Administration discover that taking the medicine may scale back the dangers of later growing lengthy COVID, in response to a new examine that was posted on-line this weekend and has not but undergone peer assessment.
“We have already identified for a while now that Paxlovid reduces the chance of acute issues,” says Dr. Ziyad Al-Aly, chief of analysis and growth on the VA Saint Louis Healthcare System, and co-author of the examine, “Now we’re including the statement that Paxlovid additionally reduces the chance of lengthy COVID.”
The drug, which has been out there within the U.S. for nearly a 12 months, is supplied without spending a dime by the federal authorities at pharmacies throughout the nation. It requires a prescription, and sufferers with COVID-19 should begin it inside 5 days of symptom onset.
Much less virus, much less lengthy COVID?
Within the examine, lengthy COVID was outlined as growing a number of signs — together with coronary heart points, blood issues, fatigue and hassle respiration — one to 3 months after testing optimistic. By these metrics, sufferers that took Paxlovid had been 26% much less more likely to develop lengthy COVID.
To get to this discovering, the researchers combed by digital well being information from greater than 56,000 sufferers within the VA well being system who examined optimistic for COVID-19 between March and June 2022, and had a minimum of one threat issue for extreme illness. They in contrast well being outcomes of 9,000 sufferers that had taken Paxlovid early of their course of sickness, with 47,000 sufferers that had not.
The advantages of taking Paxlovid did not simply apply to those that had been unvaccinated. Sufferers who had been vaccinated or boosted, or had repeat COVID-19 infections, had an identical discount within the threat of growing lengthy COVID, the examine discovered.
The examine is a preprint, that means it was shared publicly earlier than being reviewed and vetted by exterior researchers. However consultants who weren’t concerned within the examine inform NPR the findings make sense, given how Paxlovid works.
The antiviral drug stops the virus from replicating in cells. “We all know that one of many key elements that predict lengthy COVID is detectable virus within the bloodstream on the time of an infection,” Dr. Peter Chin-Hong, an infectious illness doctor on the College of California, San Francisco, wrote in an e mail. “So it stands to purpose that interventions that forestall the virus from making extra copies of itself would subsequently result in a decrease threat of lengthy COVID.”
Previous research have proven that Paxlovid reduces the dangers of hospitalization and dying from COVID-19. “For the reason that set off of lengthy COVID is acute an infection with SARS-CoV-2, it makes intuitive sense that something that lowers the severity of this an infection would scale back the chance of lengthy COVID, whether or not it is Paxlovid or different antiviral therapies,” Dr. Paul Sax, an infectious illness doctor at Brigham and Girls’s Hospital in Boston, wrote in an e mail.
A place to begin
Nonetheless, consultants view the examine as solely a place to begin for exploring the potential makes use of of Paxlovid. The VA examine was observational, based mostly on information entered into affected person well being information – in Sax’s view, “the imprecision of the [long COVID] analysis makes definitive conclusions from this examine difficult, particularly with a retrospective assessment.”
However the worth of the examine is that it factors researchers down promising pathways for extra analysis, says Dr. Monica Gandhi, an infectious illness doctor at UCSF. “It is hypothesis-generating,” she says, “It is thrilling and hopeful [to think] that should you scale back the viral load… all the way down to undetectable [early in the illness], perhaps you possibly can forestall post-COVID signs” altogether – a idea she thinks researchers may pursue.
Each Sax and Gandhi say they’d really feel extra assured within the outcomes in the event that they had been replicated in further research, particularly in experimental, randomized managed trials that evaluate lengthy COVID outcomes in sufferers who took both Paxlovid or a placebo. The VA examine’s findings are additionally restricted by the truth that the members had been predominantly white males, elevating the chance that the advantages of Paxlovid might be totally different in different teams of sufferers.
At present, Paxlovid is barely approved to be used in sufferers who’ve threat elements – like being older or having underlying well being situations – that put them at excessive threat of growing extreme illness. Al-Aly says the discount in lengthy COVID threat, raised in his examine, suggests others may profit from taking Paxlovid, too. However many sufferers who at present have lengthy COVID had been comparatively younger and wholesome earlier than they obtained COVID-19 and will not have certified for Paxlovid once they examined optimistic, he says.
“Does Paxlovid use in a lower-risk inhabitants scale back the chance of acute issues and subsequently scale back the chance of lengthy COVID?” Al-Aly wonders, “I believe that is a query that all of us want to unravel over the subsequent a number of months.”
It is also an open query whether or not the next dose or an extended therapy course may present a higher profit, Chin-Hong says.
Negative effects that embrace nausea and an off-putting style have given sufferers pause about utilizing the product. Stories of COVID rebound in Paxlovid sufferers, the place the sickness flares up after a seeming respite, has made some prescribers ambivalent concerning the product. These are actual concerns, Al-Aly says, however they need to be weighed in opposition to the advantages of Paxlovid therapy, together with decreased dangers of hospitalization and dying within the acute section, and the potential for avoiding lengthy COVID within the months after.
Gandhi says the examine’s findings might now issue into clinicians’ selections, even when the outcomes are preliminary and haven’t but been replicated.
“This examine is pushing me to make use of [Paxlovid] in people who find themselves over 65, vaccinated and boosted, as a result of it is most likely going to produce other advantages past stopping hospitalization,” she says.